Pacific Biosciences Q3 2026: A Double Beat Clouded by Margin Pressure and a CFO Exit
As seen on the 24/7 Wall St. homepage on November 4, 2026.
A double beat still came with non-GAAP gross margin compressed to 36% from 42% a year ago, as the SPRQ-Nx chemistry now driving over half of Revio consumables revenue costs more to make. Full-year revenue guidance was narrowed to $155 million to $160 million, and the CFO is leaving.
Continue ReadingShow less
Pacific Biosciences beat Wall Street on both revenue and earnings in the third quarter of 2026. Revenue came in at $40.56 million, up 5.5% year over year and ahead of the $39.46 million consensus estimate, while an adjusted loss of $0.11 per share came in better than the $0.13 analysts had expected.
The quarter turned on the rapid adoption of SPRQ-Nx chemistry, which now drives more than half of Revio consumables revenue. That transition is commercially encouraging but costly to execute. Non-GAAP gross margin compressed to 36% from 42% a year earlier, with higher memory component costs and Vega manufacturing expenses eating into profitability. Gross profit itself fell 15.3% year over year to $13.47 million even as revenue grew, underscoring how much the product mix shift is weighing on the income statement.
On the instrument side, the company placed 15 Revio systems and 35 Vega units in the quarter, compared with 13 and 32 respectively in the prior-year period. Vega placements rose about 9% year over year, with more than 90% going to new customers, a positive signal for installed-base expansion. However, annualized Revio pull-through per system declined to roughly $204,000 from roughly $236,000 a year ago, a trend investors will want to monitor as SPRQ-Nx becomes the dominant consumable.
Sponsored
Management narrowed full-year 2026 revenue guidance to a range of $155 million to $160 million. The CFO's departure adds a layer of leadership uncertainty heading into the final quarter, with interim finance leadership now in place. Cash and investments also fell to $199.4 million from $279.5 million at year-end, and the company carries $643 million of convertible senior notes, leaving the balance sheet as an ongoing watchpoint.
CEO Mark Van Oene pointed to growing clinical adoption, population genomics programs, and collaborations in AI as the avenues management expects to expand addressable markets. Partnerships announced in the quarter include a collaboration with GeneDx for rare disease long-read sequencing and a multi-year arrangement with Verily Health combining HiFi data with real-world clinical data. Whether those initiatives can accelerate revenue enough to offset the gross margin headwinds from SPRQ-Nx manufacturing costs is the key question for the quarters ahead.
Mentioned: PACB